{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-115027","form_type":"8-K","ticker":null,"cik":"0001888012","company_name":"HilleVax, Inc.","filed_at":"2024-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.254346+00:00","generated_at":"2026-05-30T14:06:34.143193+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"HilleVax cuts 15 employees (25% of workforce) to reduce costs; exploring strategic alternatives","bullets":["Workforce reduction of approximately 15 employees (~25% of total workforce).","Estimated charges of ~$1.3M for severance, benefits and termination costs, expected in Q4 2024.","Company exploring continued development of norovirus vaccine candidates and business development/strategic alternatives.","Action aims to reduce operating expenses amid uncertainty over lead candidate HIL-214."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-115027","json":"https://secwatch.observer/filing/0000950170-24-115027.json","markdown":"https://secwatch.observer/filing/0000950170-24-115027.md","text":"https://secwatch.observer/filing/0000950170-24-115027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024115027/0000950170-24-115027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024115027/hlvx-20241015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:06:34.143193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2fbf7fdd1892f9b453d8d69ab927657dae0d05ae","claim":"HilleVax, Inc. announced a restructuring with charges of approximately $1.3 million (approximately 15 employees, constituting approximately 25% of the Company's workforce).","evidence_excerpt":"these vaccine candidates and other strategic alternatives. The Company currently estimates that it will incur charges associated with the workforce reduction of approximately $1.3 million primarily related to employee severance payments, benefits and related termination costs. The Company expects that the reduction in force will be substantially complete with the","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024115027/0000950170-24-115027-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.3 million"},{"label":"Headcount","value":"approximately 15 employees, constituting approximately 25% of the Company's workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}